Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Vyvanse® (lisdexamfetamine) for the Treatment of Binge-Eating Disorder

Drug Name

Vyvanse® (lisdexamfetamine dimesylate)

Developer

Shire/Takeda

Therapy Class

CNS stimulant

Current Indication

Binge-eating disorder, attention deficit hyperactivity disorder (ADHD)

Market Sector

Nutritional disorder

Development Status

Approved in the US
Expand
Close
Close
Close

Go Top